Transverse Myelitis Trial, Recruiting NCT03900221 Sponsor: Hospices Civils de Lyon Condition: Transverse Myelitis
Back to Transverse Myelitis

Transverse Myelitis Trial, Recruiting

NCT03900221
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with Multiple Sclerosis (MS), confirmed using recognised medical guidelines (called McDonald criteria)
  • Your MS can be of any type, including a single attack, relapsing-remitting, secondary progressive, or primary progressive MS
  • You have a condition called Radiologically Isolated Syndrome (RIS), meaning MS-like changes were found on a brain scan but you have no symptoms (this will be reviewed by a specialist group)
  • You have had a Clinically Isolated Syndrome (CIS), meaning a first episode of symptoms that may suggest MS
  • You have Neuromyelitis Optica (NMO) or a related condition (this will be reviewed by a specialist group)
  • You are currently pregnant — you can join at any point during your pregnancy, though joining as early as possible after finding out you are pregnant is encouraged
  • There is no age limit — children under 18 may also be included, as long as their parents give consent on their behalf
  • You are able to give your informed agreement to take part in the study
  • You are able to read and/or understand French

Who may not be able to join:

  • There are no specific exclusion criteria listed for this trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sandra VUKUSIC, Prof., Hospices Civils de Lyon

Phone: 4 72 68 13 13

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
12 August 2019
Est. completion
12 August 2036

Where this trial is recruiting

🇫🇷 France Martinique

Primary endpoints

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 during pregnancy period; Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 during post-partum period

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov